NCT00365144View on ClinicalTrials.gov

Bevacizumab and Erlotinib in Treating Patients With Metastatic Pancreatic Cancer That Did Not Respond to Previous Treatment With Gemcitabine

PHASE2CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

February 28, 2006

Primary Completion Date

January 31, 2009

Study Completion Date

March 31, 2010

Conditions
Pancreatic Cancer
Interventions
BIOLOGICAL

bevacizumab

DRUG

erlotinib hydrochloride

OTHER

laboratory biomarker analysis

Trial Locations (1)

94115

UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco

All Listed Sponsors
lead

University of California, San Francisco

OTHER

NCT00365144 - Bevacizumab and Erlotinib in Treating Patients With Metastatic Pancreatic Cancer That Did Not Respond to Previous Treatment With Gemcitabine | Biotech Hunter | Biotech Hunter